Contineum Therapeutics (CTNM) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed PepGen (PEPG) over the past year, losing 20.7% versus a loss of 32.0%. PepGen is the larger company by market cap ($356.3 million vs $340.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | PEPG |
|---|---|---|
| Share price | $8.68 | $3.78 |
| Market cap | $340.83M | $356.31M |
| 1-day change | -3.98% | -3.82% |
| YTD return | -24.06% | -41.94% |
| 1-year return | -20.69% | -32.01% |
| EPS (TTM) | $-1.77 | $-0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-59.98M | $-89.66M |
| 52-week high | $17.79 | $7.80 |
| 52-week low | $6.73 | $1.31 |
| Distance from 52-week high | -51.19% | -51.54% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +146.89% | +263.76% |
| Average volume | 776.03K | 3.26M |
| Shares outstanding | 35.35M | 94.26M |
| Employees | 51 | 53 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed PEPG by 11.3 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees
CTNM vs PEPG FAQ
Which is bigger, Contineum Therapeutics or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $356.31M compared with $340.83M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, CTNM or PEPG?
CTNM returned -20.69% over the past 12 months, compared with -32.01% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.